ACAD - ACADIA Pharmaceuticals Inc.
| Previous Close | 25.70 |
| Open | 25.60 |
| Bid | 0.00 x 3200 |
| Ask | 0.00 x 1300 |
| Day's Range | 25.60 - 26.06 |
| 52 Week Range | 12.77 - 28.67 |
| Volume | 1,576,113 |
| Avg. Volume | 995,990 |
| Market Cap | 3.744B |
| Beta (3Y Monthly) | 1.99 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Jul 31, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 32.55 |
- MarketWatch•9 hours ago
Acadia stock drops as schizophrenia drug doesn't pass clinical trial
Acadia Pharmaceuticals Inc. shares dropped in the extended session Monday after the biotech drug maker said its schizophrenia treatment did not pass a late-stage clinical trial. Acadia shares fell 15% after hours, following a 1.1% rise to close the regular session at $25.97. In a Phase 3 clinical trial, Acadia said that its treatment pimavanserin did not perform better than a placebo on a statistically significant basis when added to an existing antipsychotic treatment for schizophrenia. By Monday's close, Acadia shares had gained nearly 61% on the year, compared with a 19% rise in the S&P 500 index and a 24% gain in the Nasdaq Composite Index .
- Reuters•9 hours ago
Acadia's schizophrenia treatment misses late-stage main goal; shares fall 16%
In the study, 396 patients with moderate-to-severe psychotic symptoms were given Acadia's treatment pimavanserin or placebo as an add-on to their current antipsychotic treatment, the company said. Adding pimavanserin to existing antipsychotic treatment showed a consistent trend in improvement of psychotic symptoms, however, the results did not show statistical significance in achieving the main goal, Acadia said.
- Reuters•10 hours ago
Acadia's schizophrenia treatment fails to meet main goal of late-stage study
- Business Wire•10 hours ago
ACADIA Pharmaceuticals Announces Top-line Results from Phase 3 ENHANCE Trial of Pimavanserin as Adjunctive Treatment for Patients with Schizophrenia
- Pimavanserin did not achieve statistical significance on the primary endpoint, but showed a consistent trend in improvement of psychotic symptoms
- TheStreet.com•12 hours ago
Acadia Falls Sharply in After-Hours Trading After Schizophrenia Drug Fails Study
Stock drops as Pimavanserin study finds no statistically significant improvement in adult schizophrenia patients.
- Business Wire•6 days ago
ACADIA Pharmaceuticals to Announce Second Quarter 2019 Financial Results on July 31, 2019
ACADIA Pharmaceuticals Inc. (ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its financial results for the second quarter ended June 30, 2019 on Wednesday, July 31, 2019, after the U.S. financial markets close. ACADIA’s management will host a conference call and webcast on Wednesday, July 31, 2019, at 4:30 p.m. Eastern Time to discuss ACADIA’s financial results and operations. The conference call may be accessed by dialing 855-638-4820 for participants in the United States or Canada and 443-877-4067 for international callers (reference passcode 1288895).
- Simply Wall St.•12 days ago
Does ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Salary Reflect Performance?
Steve Davis has been the CEO of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) since 2015. This analysis aims first to...
- PR Newswire•28 days ago
New National Event Series "Parkinson's IQ + You" Launches to Educate and Empower Parkinson's Disease Patients and Care Partners
NEW YORK and SAN DIEGO, June 25, 2019 /PRNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) and ACADIA Pharmaceuticals announce the launch of "Parkinson's IQ + You," a series of local events across the United States in 2019 and 2020 to educate and empower patients and their care partners. Parkinson's IQ + You will host live events to support Parkinson's families in learning more about the disease, the elements of a comprehensive care team, communication between patients and their doctors, the latest PD treatments and those in development, and the value of participating in clinical studies.
- Markit•last month
See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc NASDAQ/NGS:ACADView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is moderate for ACAD with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding ACAD are favorable, with net inflows of $3.03 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Insider Monkey•last month
Is ACADIA Pharmaceuticals Inc. (ACAD) A Good Stock To Buy?
Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying before the Q4 market crash that the stock market is overvalued due to a low interest rate environment that leads to companies swapping their equity for debt and focusing mostly on short-term performance such as beating the quarterly earnings estimates. In the first […]
- Simply Wall St.•last month
When Will ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Turn A Profit?
ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD): ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the...
- Business Wire•2 months ago
ACADIA Pharmaceuticals to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
ACADIA Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Goldman Sachs 40th Annual Global Healthcare Conference on Tuesday, June 11, 2019 at 1:20 p.m.
- Business Wire•2 months ago
ACADIA Pharmaceuticals to Present Phase 2 CLARITY Results for Pimavanserin as an Adjunctive Treatment in Major Depressive Disorder at the 2019 American Psychiatric Association Annual Meeting
ACADIA Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced it will present data from its Phase 2 CLARITY study, which evaluated the efficacy, safety, and tolerability of pimavanserin as an adjunctive treatment for major depressive disorder at the ...
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of ACAD earnings conference call or presentation 1-May-19 8:30pm GMT
Q1 2019 ACADIA Pharmaceuticals Inc Earnings Call
- Motley Fool•2 months ago
Why Acadia Pharmaceuticals Stock Slumped in April
The contentious drug-pricing debate weighed on Acadia Pharmaceuticals' shares last month.
- Business Wire•3 months ago
ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2019
ACADIA Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Bank of America Merrill Lynch Health Care Conference 2019 on Tuesday, May 14, 2019 at 10:40 a.m.
Motley Fool•3 months agoAcadia Pharmaceuticals (ACAD) Q1 2019 Earnings Call Transcript
ACAD earnings call for the period ending March 31, 2019.
- Zacks•3 months ago
Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Tops Revenue Estimates
Acadia (ACAD) delivered earnings and revenue surprises of -9.26% and 6.17%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•3 months ago
Acadia: 1Q Earnings Snapshot
On a per-share basis, the San Diego-based company said it had a loss of 59 cents. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
- Business Wire•3 months ago
ACADIA Pharmaceuticals Reports First Quarter 2019 Financial Results
- 1Q19 Net Sales Grew to $63.0 Million, a 29% Increase Over 1Q18- Updated 2019 Net Sales Guidance to $280 Million to $300 Million- Completed Enrollment in Two Late-Stage Adjunctive
- Insider Monkey•3 months ago
Were Hedge Funds Right About Flocking Into ACADIA Pharmaceuticals Inc. (ACAD)?
Is ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, expert networks, and get tips from investment bankers and industry insiders. Sure they sometimes fail miserably but historically their consensus stock […]
- American City Business Journals•3 months ago
Analysts point to potential Biogen M&A options after Alzheimer's failure
Is Biogen continuing to strike out? Coming off the company's first earnings call since its lead Alzheimer's disease drug failed, some analysts think so.
